Temporal trends and risks factors for antimicrobial resistant Enterobacteriaceae urinary isolates from outpatients in Guadeloupe

BMC Microbiology

Volumn 16, Issue 1, 2016, Pages

  Guyomard Rabenirina, Stéphanie ^a   Malespine, Joyce ^a   Ducat, Célia ^a   Sadikalay, Syndia ^a   Falord, Mélanie ^a   Harrois, Dorothée ^b   Richard, Vincent ^e   Dozois, Charles ^f   Breurec, Sébastien ^a,c,d   Talarmin, Antoine ^a  

^a Institut Pasteur de Guadeloupe   (Guadeloupe)

^b Centre Hospitalier de Basse Terre   (France)

^c UNIVERSITÉ DES ANTILLES   (France)

^d Centre Hospitalier Universitaire Pointe a Pitre   (Guadeloupe)

^e Institut Pasteur de Nouvelle Caledonie Noumea   (New Caledonia)

^f INRS INSTITUT ARMAND FRAPPIER   (Canada)

Author keywords

Antibiotic resistance; Enterobacteriaceae; Urinary tract infections

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFALOTIN; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN TROMETAMOL; GENTAMICIN; IMIPENEM; NALIDIXIC ACID; NITROFURANTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TICARCILLIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GUADELOUPE; HUMAN; INFANT; KLEBSIELLA PNEUMONIAE; MALE; NONHUMAN; PRESCRIPTION; PROSPECTIVE STUDY; RISK FACTOR; TREND STUDY; URINALYSIS; CLASSIFICATION; COMMUNITY ACQUIRED INFECTION; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; OUTPATIENT; PRESCHOOL CHILD; URINARY TRACT INFECTION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; GUADELOUPE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OUTPATIENTS; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 84975789842     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/s12866-016-0749-9     Document Type: Article

References (43)

1. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13:269-84.
2. Bishop MC. Uncomplicated Urinary Tract Infection. EAU Updat Ser. 2004;2:143-50.
3. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother. 2011;66:1-14.
4. Kahlmeter G, Menday P. Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European ECO.SENS Project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections. J Antimicrob Chemother. 2003;52:128-31.
5. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: The ECO SENS study revisited. Int J Antimicrob Agents. 2012;39:45-51.
6. Bercion R, Mossoro-Kpinde D, Manirakiza A, Le Faou A. Increasing prevalence of antimicrobial resistance among Enterobacteriaceae uropathogens in Bangui, Central African Republic. J Infect Dev Ctries. 2009;3:187-90.
7. Sire JM, et al. Antimicrobial resistance in outpatient Escherichia coli urinary isolates in Dakar, Senegal. J Infect Dev Ctries. 2007;1:263-8.
8. SPILF 2014 Mise au point Diagnostic et Antibiothérapie des infections Urinaires Bactériennes Communautaires de l'Adulte. Splif. 2014. http://www.infectiologie.com/UserFiles/File/medias/Recos/2014-infections-urinaires-long.pdf.
9. CA-SFM. Comite de l'Antibiogramme de la Societe Francaise de Microbiologie: Recommandations. 2013. Edition de janvier 2013.
10. Saladin M, et al. Diversity of CTX-M beta-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. FEMS Microbiol Lett. 2002;209:161-8.
11. Arlet G. Rouveau, M. & Philippon, a. Substitution of alanine for aspartate at position 179 in the SHV-6 extended-spectrum beta-lactamase. FEMS Microbiol Lett. 1997;152:163-7.
12. Eckert C, et al. Dissemination of CTX-M-Type β -Lactamases among Clinical Isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother. 2004;48:1249-55.
13. Hryniewicz K, et al. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother. 2001;47:773-80.
14. Bruyère F, Vidoni M, Péan Y, Ruimy JA, Elfassi R. Analyse microbiologique de plus de 600 infections urinaires fébriles prises en charge dans un réseau de soin. Progrès en Urol. 2013;23:890-8.
15. Ironmonger D, et al. Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years. J Antimicrob Chemother. 2015;70:1744-50.
16. Laupland KB, Ross T, Pitout JDD, Church DL, Gregson DB. Community-onset urinary tract infections: A population-based assessment. Infection. 2007;35:150-3.
17. Magliano E, et al. Gender and age-dependent etiology of community-acquired urinary tract infections. ScientificWorldJournal. 2012;2012:349597.
18. Maraki S, Mantadakis E, Michailidis L, Samonis G. Changing antibiotic susceptibilities of community-acquired uropathogens in Greece, 2005-2010. J Microbiol Immunol Infect. 2013;46:202-9.
19. Lu PL, et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents. 2012;40:S37-43.
20. Hanley J, Branford I, Gugnan HC, Wilkinson C. U. T. urinary bacterial pathognes in St. Kitts.pdf. West Indies Med J. 2009;58:670.
21. Kothari A, Sagar V. Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study. J Infect Dev Ctries. 2008;2:354-8.
22. Akoachere J-FTK, Yvonne S, Akum NH, Seraphine EN. Etiologic profile and antimicrobial susceptibility of community-acquired urinary tract infection in two Cameroonian towns. BMC Res Notes. 2012;5:219.
23. Fosse-Edorh S. Journée modiale du diabète. Beh. 2014;30-31:491-529.
24. Ronald A. The etiology of urinary tract infection: Traditional and emerging pathogens. Dis Mon. 2003;49:71-82.
25. Raz R, Colodner R, Kunin CM. Who are you - Staphylococcus saprophyticus? Clin Infect Dis. 2005;40:896-8.
26. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother. 2012;56:2181-3.
27. Schito GC, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009;34:407-13.
28. Randrianirina F, et al. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar. J Antimicrob Chemother. 2007;59:309-12.
29. Ma KL, Wang CX. Analysis of the spectrum and antibiotic resistance of uropathogens in vitro: Results based on a retrospective study from a tertiary hospital. Am J Infect Control. 2013;41:601-6.
30. Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JDD. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect. 2008;57:441-8.
31. Arpin C, et al. Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting. J Antimicrob Chemother. 2009;63:1205-14.
32. Pitout JDD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159-66.
33. Smith SP, Manges AR, Riley LW. Temporal changes in the prevalence of community-acquired antimicrobial-resistant urinary tract infection affected by Escherichia coli clonal group composition. Clin Infect Dis. 2008;46:689-95.
34. Breurec S, et al. Klebsiella pneumoniae resistant to third-generation cephalosporins in five African and two Vietnamese major towns: Multiclonal population structure with two major international clonal groups, CG15 and CG258. Clin Microbiol Infect. 2013;19:349-55.
35. Kumarasamy KK, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597-602.
36. Bastian S, et al. First case of NDM-1 producing Klebsiella pneumoniae in Caribbean islands. Int J Infect Dis. 2015;34:e53-4.
37. Breurec S, et al. Emergence of OXA-48-producing Escherichia coli in the Caribbean islands. J Glob Antimicrob Resist. 2015;3:217-8.
38. Andrade SS, et al. Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: Time for local guidelines? Mem Inst Oswaldo Cruz. 2006;101:741-8.
39. Vernaz N, et al. Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. J Antimicrob Chemother. 2011;66:928-35.
40. Grignon O, et al. Escherichia coli antibiotic resistance in emergency departments. Do local resistance rates matter? Eur J Clin Microbiol Infect Dis. 2014;34:571-7.
41. Heginbothom ML, et al. Laboratory testing policies and their effects on routine surveillance of community antimicrobial resistance. J Antimicrob Chemother. 2004;53:1010-7.
42. Dromigny JA, Nabeth P, Juergens-Behr A, Perrier-Gros-Claude JD. Risk factors for antibiotic-resistant Escherichia coli isolated from community-acquired urinary tract infections in Dakar, Senegal. J Antimicrob Chemother. 2005;56:236-9.
43. Dalhoff A. Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis. 2012;2012:976273.